Reported Gross News Today

  AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines 1, the Company leveraged its revenue growth to make further progress in profitability, while the strategy of sustainable growth through innovation brought numerous further benefits for patients. AstraZenecas patient-centric strategy, focus on innovation and capital-allocation priorities remain unchanged,...

Updated Jan 20, 2021 | 18:34 IST Capital adequacy is good for next 3 years. Structural transformation is changing operating processes and that would mean change in technology stack, this process will be completed by May 2021: Rajeev Jain. Representational Image&nbsp | &nbspPhoto Credit:&nbspBCCL Key Highlights Outlook: “The company expects core AUM growth to resume to pre-COVID levels by Q4 FY21” Outlook: "FY22 onwards, see loan losses & prov seen at 160-170bps of av...